Amrutanjan Health Care Ltd
Amrutanjan Health Care Ltd Q2 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q2 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Amrutanjan Health Care Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q2 FY25 Net Sales: Rs. EBITDA: Not explicitly reported in the presentation. - Operating Margin: - Half Year (H1 FY25) increased from 6.24% to 7.18%. - Target for full year FY25 is to increase operating margin to 13% from 10.9% in the previous year. - Profit After Tax (PAT) for Q2 FY25: - Rs.
From Amrutanjan Health Care Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY25 Net Sales: Rs. 109.92 Cr, up 10.68% YoY.
- Q2 FY25 OTC Sales: Rs. 106.26 Cr, up 12.95% YoY.
- Q2 FY25 Comfy Sales: Rs. 33.00 Cr, up 27.96% YoY.
- Q2 FY25 Beverages Sales: Rs. 3.39 Cr, down from Rs. 4.88 Cr YoY.
- Q2 FY25 Electro Plus Sales: Rs. 3.16 Cr, slightly down from Rs. 3.25 Cr YoY.
- H1 FY25 Net Sales: Rs. 193.65 Cr, up 9.30% YoY.
- H1 FY25 OTC Sales: Rs. 178.89 Cr, up 11.65% YoY.
- H1 FY25 Comfy Sales: Rs. 59.58 Cr, up 30.54% YoY.
- H1 FY25 Beverages Sales: Rs. 14.34 Cr, up 12.20% YoY.
- Brand Comfy grew 28% in Q2 and 31% in H1.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹150 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key investor presentation takeaways from Wockhardt
- Anuh Pharma Ltd (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY25 investor presentation — and how it ranks against sec
- Themis Medicare Ltd (Q2 FY25)
117.01 Cr, up 11.67% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY25 investor presentation — and how it ranks against sector
- Lincoln Pharmaceuticals Ltd (Q2 FY25)
EBITDA**: ₹1,234 crore, up 15% YoY . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY25 investor presentation — and how it ranks aga
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q2 FY25 results?
Q2 FY25 Net Sales: Rs. EBITDA: Not explicitly reported in the presentation. - Operating Margin: - Half Year (H1 FY25) increased from 6.24% to 7.18%. - Target for full year FY25 is to increase operating margin to 13% from 10.9% in the previous year. - Profit After Tax (PAT) for Q2 FY25: - Rs.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amrutanjan Health Care Ltd planning capital expenditure?
The investor presentation for Amrutanjan Health Care Limited does not explicitly describe any capex, capacity expansion, new plant, or project details including amounts, status, or timelines.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.